Isolators for ATMPs: The Challenge of Manufacturing ATMPs in Sterile Environments

Advanced Therapy Medicinal Products (ATMPs), such as cell therapies, gene therapies, and tissue-engineered products, present unique manufacturing challenges.

Unlike traditional pharmaceuticals, these biological products generally cannot undergo terminal sterilization. As a result, continuous monitoring of critical environmental production parameters—such as temperature, humidity, and particle counts—is essential to ensure process integrity and product quality.

One of the main risks in ATMP manufacturing is microbiological contamination, which can compromise both product quality and patient safety. Good Manufacturing Practice (GMP) regulations allow production to be carried out in either open or closed systems:

• Open systems: Require a Grade A clean area within a Grade B background environment, resulting in high operating costs and complex infrastructure requirements.
• Closed systems (isolators): Enable Grade A production conditions within a Grade D environment, enhancing safety while significantly reducing cleanroom investment and operating costs.

In this context, Litek Pharma isolators represent the optimal solution for the safe and efficient manufacturing of ATMPs.

Litek Pharma Isolator Technology: Safety, Efficiency, and GMP Compliance

Litek Pharma isolators are designed to provide a sterile, airtight, and controlled environment, ensuring the integrity of ATMPs from manufacturing through to product release. Key features include:

Sterile and Validated Production Environment

Litek Pharma isolators provide a Grade A environment protected by a HEPA-filtered ventilation system with unidirectional airflow, maintaining conditions free from particulate and microbial contamination.

Safe and Automated Decontamination

The hydrogen peroxide vapor (H₂O₂) decontamination system achieves a validated 6-log reduction before production begins, ensuring a repeatable and verifiable sterility assurance level.

Aseptic Transfer Systems

To prevent cross-contamination, the isolators are equipped with advanced material transfer solutions.

The modular design allows the integration of one or two airlocks, as well as material transfer systems utilizing Vaporized Hydrogen Peroxide (VHP). These systems effectively decontaminate materials before their introduction into the isolator, ensuring a controlled and secure manufacturing environment.

Integration with Manufacturing Equipment

The modular architecture of Litek Pharma isolators enables seamless integration with essential ATMP production equipment, including:

• Centrifuges
• CO₂ incubators
• Microscopes
• Fill & Finish solutions
• Lyophilizers

Compliance with International Standards

Litek Pharma isolators comply with the highest regulatory standards, including:

• GMP Part IV – Advanced Therapy Medicinal Products (ATMPs)
• EU GMP Annex 1 (Manufacture of Sterile Medicinal Products)
• ISO 14644-7 (Cleanrooms and Associated Controlled Environments – Separative Devices)
• ISO 10648-2 (Containment Enclosures – Classification According to Leak Tightness and Associated Checking Methods)

Benefits of Isolators in ATMP Manufacturing

The implementation of isolator technology in advanced therapy manufacturing provides significant advantages for the biopharmaceutical industry:

• Enhanced product safety by eliminating the risk of external contamination.
• Reduced operational costs through lower cleanroom classification requirements.
• Full regulatory compliance, facilitating process validation and qualification.
• Improved operator protection when handling high-risk biological products.

Litek Pharma isolators are specifically designed to adapt to the unique requirements of ATMP manufacturing processes, providing a scalable, efficient, and fully compliant solution for advanced therapy production.

Contact Us

Contact us to learn more about our isolator solutions and their application in ATMP manufacturing.